| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 6, Issue 2 131-137, Copyright © 1995 by American Association of Cancer Research
ARTICLES |
T Subramanian, B Tarodi and G Chinnadurai
Institute for Molecular Virology, St. Louis University Medical Center, Missouri 63110, USA.
Adenovirus E1B 19K protein prevents premature death of adenovirus-infected cells. Viral mutants (19K mutants) defective in the 19K protein induce enhanced cell death, resulting in fragmentation of viral and cellular DNA. The 19K protein can also suppress the effects of certain external cell death-inducing stimuli, such as tumor necrosis factor alpha and various DNA-damaging agents that induce apoptosis. We have examined viral infection of permissive human cells and nonpermissive rat cells to determine if the 19K mutant induces apoptotic or necrotic type of cell death. Infection of normal rat kidney cells with an adenovirus type 2 19K deletion mutant induces internucleosomal DNA fragmentation and condensation of nuclear chromatin. Electron microscopic examination of these cells revealed the presence of condensed subnuclear bodies characteristic of apoptosis. In contrast, infection of human A549 cells induces random DNA fragmentation, and these cells do not exhibit characteristic condensation of the nuclear chromatin but contain enlarged nuclei loaded with virus particles. Therefore, it appears that adenovirus infection induces both apoptotic and necrotic types of cell death, depending on the cell type. Both types of cell death can be suppressed by E1B 19K protein. Similarly, a recombinant adenovirus expressing the human Bcl-2 protein but lacking the E1B proteins can efficiently suppress both apoptotic and necrotic cell death induced by adenovirus infection. The requirement of p53 tumor suppressor protein in adenovirus-induced cell death was investigated by infection of human Saos2 and mouse p53 nullizygous (p53-/-) cells lacking p53 tumor suppressor protein.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
![]() |
T. Subramanian, S. Vijayalingam, E. Lomonosova, L.-j. Zhao, and G. Chinnadurai Evidence for Involvement of BH3-Only Proapoptotic Members in Adenovirus-Induced Apoptosis J. Virol., October 1, 2007; 81(19): 10486 - 10495. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. V. Gurova, O. W. Rokhlin, A. V. Budanov, L. G. Burdelya, P. M. Chumakov, M. B. Cohen, and A. V. Gudkov Cooperation of Two Mutant p53 Alleles Contributes to Fas Resistance of Prostate Carcinoma Cells Cancer Res., June 1, 2003; 63(11): 2905 - 2912. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lomonosova, T. Subramanian, and G. Chinnadurai Requirement of BAX for Efficient Adenovirus-Induced Apoptosis J. Virol., October 11, 2002; 76(22): 11283 - 11290. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cuconati and E. White Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection Genes & Dev., October 1, 2002; 16(19): 2465 - 2478. [Full Text] [PDF] |
||||
![]() |
D. de Moissac, S. Mustapha, A. H. Greenberg, and L. A. Kirshenbaum Bcl-2 Activates the Transcription Factor NFkappa B through the Degradation of the Cytoplasmic Inhibitor Ikappa Balpha J. Biol. Chem., September 11, 1998; 273(37): 23946 - 23951. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Marcellus, J. N. Lavoie, D. Boivin, G. C. Shore, G. Ketner, and P. E. Branton The Early Region 4 orf4 Protein of Human Adenovirus Type 5 Induces p53-Independent Cell Death by Apoptosis J. Virol., September 1, 1998; 72(9): 7144 - 7153. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Uhlmann, T. Subramanian, C. A. Vater, R. Lutz, and G. Chinnadurai A Potent Cell Death Activity Associated with Transient High Level Expression of BCL-2 J. Biol. Chem., July 10, 1998; 273(28): 17926 - 17932. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Li, A. Yu, and A. M. Weiner Adenovirus Type 12-Induced Fragility of the Human RNU2 Locus Requires p53 Function J. Virol., May 1, 1998; 72(5): 4183 - 4191. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Nash, M. B. Purner, R. P. Leon, P. Clarke, R. C. Duke, and T. J. Curiel Toxoplasma gondii-Infected Cells Are Resistant to Multiple Inducers of Apoptosis J. Immunol., February 15, 1998; 160(4): 1824 - 1830. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Moallem and B. Hales The role of p53 and cell death by apoptosis and necrosis in 4-hydroperoxycyclophosphamide-induced limb malformations Development, January 8, 1998; 125(16): 3225 - 3234. [Abstract] [PDF] |
||||
![]() |
S. Y. Hsu, A. Kaipia, E. McGee, M. Lomeli, and A. J. W. Hsueh Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members PNAS, November 11, 1997; 94(23): 12401 - 12406. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Kirshenbaum and D. de Moissac The bcl-2 Gene Product Prevents Programmed Cell Death of Ventricular Myocytes Circulation, September 2, 1997; 96(5): 1580 - 1585. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |